Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitokiren malate plus amlodipine for primary mild to moderate hypertension with early renal injury risk
ChiCTR2600133505Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sitokiren, amlodipine and allisartan isoproxil in essential hypertension (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Change from baseline in mean sitting diastolic blood pressure. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sitokirenamlodipineallisartan isoproxil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2600133505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133505.